Does Stronger Volume Performance Make BAT a Buy?

Altria (NYSE: MO) and British American Tobacco (NYSE: BTI) both have attractively large yields, at 7.4% and 7.7%, respectively. By comparison, the S&P 500 index is only yielding 1.2% while the average consumer staples stock has a yield of roughly 2.7%. There’s just one problem: The main product made by these two companies, cigarettes, is in decline. But there’s a difference in the rates of decline Altria and British American Tobacco are facing.

Cigarettes were once viewed as cool and it wasn’t a stigma to be a smoker. The realization that these tobacco products are addictive and cause cancer changed all of that. And today the business is facing a long-running decline in volumes. This is particularly true in North America, where Altria is focused. But it isn’t a trend that’s unique to North America, as globally diversified British American Tobacco has been dealing with ongoing volume declines as well.

A person breaking a cigarette in half.
Image source: Getty Images.

The numbers are troubling. Altria’s volume declined 9.7% in 2022, 9.9% in 2023, and 10.2% in 2024. Not only is the rate of decline shocking, but it appears to be getting worse. If this were any other consumer staples company, investors would be running for the hills.

British American Tobacco’s global diversification has helped to soften the declines, but they are still a big issue. In 2022 its volume declined 5.1%, in 2023 the drop was 5.3%, and in 2024 it was 5%. The 2023 and 2024 volume numbers exclude the impact of the sale of the company’s Russian and Belarus businesses.

For an investor interested in a high-yield stock, it certainly looks like the fundamentals underpinning British American Tobacco’s business are stronger given these volume trends. But does that mean you should buy it?

So far, both Altria and British American Tobacco have used the same basic game plan to deal with falling volumes: They have been raising prices. That has worked out well, allowing both to support and even grow their dividends despite the fact that their businesses continue to hemorrhage customers. It seems likely that raising prices can only go on for so long before there’s an inflection point and the price increases simply make the volume decline speed up. Given the trend at Altria, that time might be now for the maker of Marlboro.

British American Tobacco has the rest of the world to help offset the hit it is taking in the United States, but there’s still a notable highlight to consider here. In 2023 the company changed the way it accounts for its U.S. brands, effectively admitting that they are likely to be worthless in a little less than 30 years. That’s a massive admission as to the depth of the problem the company, and the industry more broadly, face today.

For investors with a long time horizon, the question that should be asked is whether tobacco as an industry is the right one to bet on. For most the answer will probably be no, particularly if you need the income from your stock portfolio to pay for living expenses. And while British American Tobacco is clearly suffering less than Altria today, that’s not the same as saying British American Tobacco has a fundamentally strong business. Both companies are facing a bleak future if they can’t find a new growth platform to replace their cigarette operations.

Neither Altria nor British American Tobacco are ignoring the problems they face. Each company is working hard to find new business opportunities, such as vaping and pouches. And there probably isn’t an imminent threat to the dividends they pay, for now, thanks to ongoing price hikes.

So, short-term minded income investors might want to take the risk of buying one of these two companies. In that situation, British American Tobacco’s higher yield and better volume performance suggest it should probably be the top choice. However, if you think in decades and not days, neither of these cigarette makers appears to have the business fundamentals to support buying them.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $292,207!*

  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,326!*

  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $480,568!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Continue »

*Stock Advisor returns as of March 3, 2025

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends British American Tobacco P.l.c. and recommends the following options: long January 2026 $40 calls on British American Tobacco and short January 2026 $40 puts on British American Tobacco. The Motley Fool has a disclosure policy.

British American Tobacco vs. Altria: Does Stronger Volume Performance Make BAT a Buy? was originally published by The Motley Fool

https://media.zenfs.com/en/motleyfool.com/3ca6551c31c47b0d40984a258bb0dcd2

2025-03-08 07:52:00

Exit mobile version